Lahore, September 20, 2024 — In a historic achievement, Citi Pharma Limited has announced its entry into the U.S. market, becoming Pakistan’s first exporter of nutraceutical products to the United States. The announcement, made in a statement on Friday, marks a significant milestone in the country’s pharmaceutical industry.
Citi Pharma, known as Pakistan’s largest active pharmaceutical ingredient (API) manufacturer, achieved this feat following the FDA approval of several nutraceutical products in key categories such as fertility, weight management, stress and mood enhancement, hair and skin care, and joint and muscle pain relief. The ground-breaking launch in September 2024 cements Citi Pharma’s reputation for adhering to rigorous international quality standards, allowing them to compete in one of the world’s most challenging and lucrative markets.
CEO Rizwan, the visionary behind this initiative, emphasized the importance of maintaining world-class standards in product development. “This is a testament to our unwavering commitment to quality and purity. We are proud to bring Pakistan into the global spotlight by offering the highest quality nutraceuticals to a demanding market like the U.S.,” he said.
Citi Pharma’s product line is diverse and comprehensive, featuring tablets, capsules, powder sachets, syrups, ointments, gels, injections, and infusions. What sets the company apart is its dedication to delivering the best care for life, reflected in its state-of-the-art manufacturing processes and its focus on both local and global markets.
This FDA approval unlocks significant financial opportunities for Citi Pharma, with expectations to generate approximately $3 million annually from this new revenue stream. The company anticipates profit margins of 25% to 30%, making this venture not only a validation of their product line but also a highly profitable one. Furthermore, the approval is expected to boost Citi Pharma’s global credibility, attracting potential investors and international partnerships, solidifying its place as an emerging global player in the pharmaceutical sector.
The first shipment, which has already been dispatched, has generated $109,500 in revenue, setting a strong foundation for future exports. This landmark moment marks the beginning of Citi Pharma’s journey towards expanding its footprint in the international market, particularly in the U.S., where the demand for high-quality nutraceuticals continues to rise.
With its ongoing dedication to innovation, quality, and global expansion, Citi Pharma Limited is positioned to become a game-changer in the nutraceutical industry, both in Pakistan and worldwide.
